Compare AFLAC Incorporated (AFL) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Gilead Sciences, Inc. — how do they compare? AFLAC Incorporated trades at $121.06 (market cap $61.13B), while Gilead Sciences, Inc. trades at $135 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 2.7× AFLAC Incorporated's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| AFL | GILD | |
|---|---|---|
Market Cap | $61.13B | $164.99B |
Sector | Financials | Health |
52-Week High | $129.55 | $155.80 |
52-Week Low | $103.55 | $110.56 |
Enterprise Value | $71.08B | $188.06B |
Dividend Yield | 2% | 2.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
